Percentage of patients experiencing each adverse event
|
Gold No (%) |
Methotrexate No (%) | |
| Nausea/anorexia | 0 | 13 (19) |
| Abdominal pain | 1 (1) | 2 (3) |
| Diarrhoea | 3 (4) | 5 (7) |
| Proteinuria >250 mg/24 h | 11 (15) | 1 (1) |
| Proteinuria <250 mg/24 h | 8 (11) | 1 (1) |
| Haematuria | 1 (1) | 1 (1) |
| Skin rash | 12 (17) | 7 (10) |
| Pruritis | 4 (6) | 2 (3) |
| Hair loss/alopecia | 2 (3) | 0 |
| Mouth ulcers/stomatitis | 11 (15) | 10 (14) |
| Vasovagal | 1 (1) | 0 |
| Leucopenia <4×109/l | 5 (7) | 3 (4) |
| Thrombocytopenia <150×109/l | 4 (6) | 0 |
| Increased transaminases <2×normal | 3 (4) | 4 (6) |
| Increased transaminases >2×normal | 2 (3) | 8 (12) |
| Hypogammaglobulinaemia | 0 | 0 |
| Pulmonary toxicity | 0 | 0 |
| Breathlessness (pneumonitis not proved) | 1 (1) | 1 (1) |
| Infection | 4 (6) | 11 (16) |
| Life threatening infection | 0 | 1 (1) |
| Increased nodules | 1 (1) | 3 (4) |
| New nodules (previously none) | 0 | 4 (6) |
| Haematological neoplasm | 0 | 0 |
| Neoplasm | 0 | 1 (1) |